# Tessellate BIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tessellate-bio

- Industry: Biotechnology
- Headquarters: Naarden, Netherlands
- Website: www.tessellatebio.com/
- Total disclosed funding: $8.5M
- Latest round: Seed (Oct 17, 2023)
- Investors on record: 2

## About

Based in Naarden, Netherlands, and founded in 2020, Tessellate BIO BV operates as a biotechnology company that focuses on redefining synthetic lethality to help patients with cancer. In 2023, Tessellate BIO BV raised EUR 8 million in seed funding from BioGeneration Ventures and Forbion.

Tessellate BIO's product portfolio is centered around a comprehensive approach to synthetic lethality in cancer. Tessellate BIO's solutions are tumor-agnostic they are tailored to the genotype or phenotype of the cancer, not the tissue of origin. The approach is underpinned by a commitment to precision medicine, where companion diagnostics play a pivotal role. By focusing on targets, the company creates treatments that enhance the quality of life and survival rates for cancer patients.

The company plans to use the seed funding to further develop its product offerings.

## Funding rounds

- Seed, Oct 17, 2023, $8.5M — Forbion, BioGeneration Ventures

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed